Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test BioPharma DiveThe results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy.Immunology & InflammationRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) BioPharma Dive The results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Beren pockets $300m to take Niemann-Pick disease therapy to marketNext: SonoThera bags $125M series B to advance safer gene therapies Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
